Skip to content

David M. Margolis

  • M.D.
  • Professor UNC School of Medicine, Director UNC HIV Cure Center
  • University of North Carolina at Chapel Hill
  • 56h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 9159CitationsNumber of citations received by David M.'s publications. Updated daily.

About

the Director of the UNC HIV Cure Cneter and a professor of Medicine, Microbiology & Immunology, and Epidemiology at the University of North Carolina at Chapel Hill, Dr. Margolis is a graduate of Tufts University School of Medicine, trained in medicine at the New England Medical Center, infectious diseases at the NIAID, and did post-doctoral research in the regulation of HIV gene expression at the University of Massachusetts Program in Molecular Medicine. His laboratory studies interactions between HIV and the host cell on the molecular level, with an eye to use these insights to improve the treatment of HIV infection, and the management of the HIV pandemic. Current work focuses on the molecular mechanisms that control the latent reservoir of HIV infection within resting T cells, disrupt latent infection, and purge residual HIV infection. The group has described selected members of the family of chromatin modifying enzymes, histone deacetylases, that act at the proviral promoter to enforce latency. The laboratory is attempting to test novel reagents that perturb latency in T cells obtained from HIV+ patients, followed by clinical experiments that attempt to deplete persistent HIV infection in small, proof-of-concept studies. Dr. Margolis is a member of the editorial board of the Journal of Infectious Diseases, and a member of the International AIDS Society, and the American Society of Clinical Investigation, and a fellow of the American College of Physicians and the Infectious Diseases Society of America.

Co-authors (690)

  • John  Ventura
  • Mark Pankau
  • Johan Van Weyenbergh

Publications (5)

  • International AIDS Society global scientific strategy: Towards an HIV cure 2016

    • Deeks S
    • Lewin S
    • Ross A
    • et al.
    N/AReaders
    86Citations
    Get full text
  • Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells

    • Sung J
    • Pickeral J
    • Liu L
    • et al.
    N/AReaders
    41Citations
    Get full text
  • Towards an HIV cure: A global scientific strategy

    • Deeks S
    • Autran B
    • Berkhout B
    • et al.
    N/AReaders
    323Citations
    Get full text
  • Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS clinical trials group 5170

    • Skiest D
    • Su Z
    • Havlir D
    • et al.
    N/AReaders
    39Citations
    Get full text
  • Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine

    • Straus S
    • Savarese B
    • Tigges M
    • et al.
    N/AReaders
    55Citations

Professional experience

Professor UNC School of Medicine, Director UNC HIV Cure Center

University of North Carolina at Chapel Hill

August 2005 - Present